Sorrento Releases Positive Results from a Phase 1b Study in China in COVID-19 Patients and is Ready for Pivotal Phase 3 trials with OVYDSO™ (STI-1558), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19 without the Need for Ritonavir Boosting
- ByBenzinga-
Topline safety, antiviral effectiveness and pharmacokinetic (PK) data from a Phase 1b Study in China are released from the single ascending dose (SAD) portion of the study with the...